Loading…
← CockpitCompetitor Analysis › 4928.T Noevir Holdings Co., Ltd.Open in the cockpit ↗

Noevir Holdings Co., Ltd.4928.TCompetitor analysis, valuation and peers

Japan · JPY·Consumer Staples›Household/Personal Care

Japanese cosmetics maker selling skincare and beauty products primarily through a direct-sales/door-to-door model.

≈ Japan's Avon/Mary Kay for direct-sales cosmeticsMomentum neutral 56
Mkt cap
$978M
US dollars, full cap
Free float
44%
of shares outstanding
$/day
$1.98M
20-day average traded
Fwd P/E
20.4×
forward earnings
ROIC−WACC
+35.2 pp
WACC 5.0%
Hurdle
-17 pp
Req g minus delivered
Next earnings
83 days
9 Feb 2027
Close · JPY¥4,565
1D-1.2%
1W+1.4%
1M-2.7%
3M-5.4%
6M+6.7%
YTD-0.3%
1Y+2.9%
ATR %2.0%
52w lowhigh10.0% off high

What Noevir does

Japanese cosmetics maker selling skincare and beauty products primarily through a direct-sales/door-to-door model.

Sells through consultants who counsel customers in person, so the company controls pricing and skips retailer margins, and sales depend on repeat customers who stay with their consultant. Skin care is the core and health foods a side line. Japan carries the business.

In one line: Japan's Avon/Mary Kay for direct-sales cosmetics.

Products and services

  • Direct-sales skincare/cosmetics
  • Health foods/supplements

Customers

  • Direct-sales beauty consultant customers

Where it sits in the supply chain

  • Consumer beauty
  • Cosmetics manufacturing & direct sales
  • Direct-sales skincare/cosmetics

What could go right

  • Direct-sales cosmetics demand stability

What could go wrong

  • Direct-sales channel secular decline
  • Cosmetics category competition

Moat: narrow (brand, distribution). Established direct-sales consultant network for skincare in Japan.

Headquarters: Kobe, Japan · Founded: 1954

Named competitors

Noevir at a glance

Size Noevir (4928.T) is a Japan Consumer Staples company (Household/Personal Care) with a market value of $978M, the 747th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥4,565 on 18 Nov 2026.

Performance Over six months the shares gained 6.7%, against +5.6% for the median peer and -1.4% for the Japan market (cap-weighted) — 11th highest of 21 in its peer set.

Growth Revenue fell 3.2% over the last twelve months (peer median +10.2%); the operating margin is 27.8% (peer median 8.6%).

Valuation It trades at 20.4× forward earnings against a peer median of 18.7× (9th most expensive of 21).

Price implies For today's price to make sense, revenue must grow about -13% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -17 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 35.2 points above its cost of capital (5.0% WACC).

Next results Next results expected around 9 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 20264928.T 109Peer median 108
Six months, rebased to 100: Noevir against the median of its 20 peers (local-currency closes).

Noevir financials

Reported figures in JPY; fiscal year ends 2026-09-30. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
Revenue¥62.7B¥62.7B¥64.7B¥63.8B¥62.6B
Revenue growth—-3%+1%+2%—
Gross profit¥42.3B¥42.3B¥43.3B¥43.2B¥42.6B
EBITDA¥18.5B¥10.5B¥11.9B¥12.4B¥12.2B
Net income¥8.22B¥8.22B¥8.03B¥7.97B¥7.67B
Free cash flown/a¥3.93B¥5.66B¥8.50B¥6.89B
Capital expendituren/a¥859M¥2.52B¥1.01B¥1.05B
Total debt¥664M¥664M¥742M¥828M¥914M

Quarterly statements and history in the cockpit →

Noevir competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%3011082657603193001328241710GALAXYSURF4836503007402145JYOTHYLAB4919EPC605009003006ICOS3013710027906003156039833009574928.T6-month return →1-month return →
Up and to the right = strong over both horizons. Noevir is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%10×20×30×40×3011082657603193001328241710GALAXYSURF4836503007402145JYOTHYLAB4919EPC605009003006ICOS3013710027906003156039833009574928.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Noevir is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%3011082657603193001328GALAXYSURF4836503007402145JYOTHYLAB49190030063013710027906003153009574928.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Noevir is the large dot.

Noevir competitors and peer comparison

Head to head with its named competitors (4928.T vs 4927.T vs 4922.T)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Noevir 4928.T$978M+7%-3%28%20.4×-12.8%
Pola Orbis 4927.T$2.04B+15%+1%11%30.6×-2.0%
KOSE 4922.T$2.16B+16%+4%5%29.9×n/a

How Noevir compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Noevir against its 20 peers (data as of 18 Nov 2026)
Measure4928.TPeer medianRank in peer set
1-month return-2.7%-2.5%11th highest of 21
6-month return+6.7%+5.6%11th highest of 21
Distance from 52-week high-10.0%-33.1%4th highest of 21
Revenue growth (TTM)-3.2%+10.2%4th lowest of 21
Operating margin27.8%8.6%highest of 21
Forward P/E20.4×18.7×9th most expensive of 21
Growth the price implies (Req g, 7 yrs)-12.8%4.4%least demanding of 18
Growth delivered (Del g)+4.1%+10.8%5th lowest of 18
Hurdle (Req g minus delivered)-16.9 pp-4.4 pp5th least demanding of 18
ROIC minus cost of capital+35.2 pp+4.7 pp3rd highest of 21
EV / EBITDA7.1×10.3×2nd cheapest of 11
Net debt / EBITDA-1.4×-0.9×4th least indebted of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Noevir 4928.TJapan$978M+7%-3%28%20.4×-12.8%+4.1%
Tongling Jieya Biologic Technology 301108.SZChina$933M+56%+24%5%52.5×28.5%+0.8%
Shanghai Forest Cabin Cosmetics 2657.HKHong Kong$1.04B+15%+74%18%11.8×11.3%+49.0%
Runben Biotechnology 603193.SSChina$918M-30%+13%21%18.5×1.5%+28.4%
Dencare (Chongqing) Oral Care 001328.SZChina$912M+13%+10%11%27.9×3.7%+10.8%
Cosmecca Korea 241710.KSSouth Korea$847M+23%+42%12%16.3×n/an/a
Galaxy Surfactants GALAXYSURF.NSIndia$845M+22%+30%9%17.6×18.5%+13.7%
d'Alba Global 483650.KSSouth Korea$1.13B-55%+49%22%12.0×-6.6%+53.0%
SYoung 300740.SZChina$816M-48%+14%3%33.4×14.0%+6.1%
Shanghai Chicmax Cosmetics 2145.HKHong Kong$1.17B-42%+23%8%14.4×-6.1%+21.2%
Jyothy Labs JYOTHYLAB.NSIndia$762M-9%+5%8%40.8×34.5%+8.9%
Milbon 4919.TJapan$743M+48%+8%14%25.7×-3.3%+8.2%
Edgewell Personal Care EPCUnited States$1.30B+67%-10%7%14.2×n/an/a
Hangzhou Haoyue Personal Care 605009.SSChina$726M-18%+10%6%17.7×4.4%+7.7%
Chongqing Baiya Sanitary Products 003006.SZChina$1.35B+27%0%3%37.3×28.8%+22.8%
Intercos ICOS.MIItaly$1.43B+12%-5%9%18.9×4.3%+11.5%
Harbin Fuerjia Technology 301371.SZChina$1.51B-39%+28%20%21.4×7.5%+3.6%
AMOREPACIFIC 002790.KSSouth Korea$1.61B+2%+9%9%8.5×-5.7%-1.3%
Shanghai Jahwa United 600315.SSChina$1.61B-15%+9%2%15.4×15.3%-2.1%
Guangdong Marubi Biotechnology 603983.SSChina$1.62B+9%-6%2%45.5×n/an/a
Yunnan Botanee Bio-Technology 300957.SZChina$1.69B-33%+7%9%19.1×2.6%+15.3%

Questions

Who are Noevir's main competitors?
Named competitors: Pola Orbis Holdings (4927.T), KOSE Holdings (4922.T). The cockpit's measured peer set (industry) also includes Tongling Jieya Biologic Technology (301108.SZ), Shanghai Forest Cabin Cosmetics (2657.HK), Runben Biotechnology (603193.SS), Dencare (Chongqing) Oral Care (001328.SZ), Cosmecca Korea (241710.KS), Galaxy Surfactants (GALAXYSURF.NS).
Is Noevir expensive compared with its peers?
On forward p/e it trades at 20.4× against a peer median of 18.7×, 9th most expensive of 21 in its peer set. For today's price to make sense, revenue must grow about -13% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -17 pp: the price already allows for a slowdown.
How has Noevir stock performed?
Over six months to 18 Nov 2026 the shares returned +6.7% against +5.6% for the median peer; over one year +2.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.